valoctocogene roxaparvovec-rvox

FDA Drug Profile — ROCTAVIAN

Drug Details

Generic Name
valoctocogene roxaparvovec-rvox
Brand Names
ROCTAVIAN
Application Number
BLA125720
Sponsor
BioMarin Pharmaceutical Inc.
NDC Codes
2
Dosage Forms
INJECTION, SUSPENSION
Routes
INTRAVENOUS
Active Ingredients
VALOCTOCOGENE ROXAPARVOVEC

Indications and Usage

1 INDICATIONS AND USAGE ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. ( 1 )